Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:1380 |
Name | endometrial cancer |
Definition | A uterine cancer that is located_in tissues lining the uterus. |
Source | DiseaseOntology.org |
Alt Ids | DOID:5654 |
Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer uterine cancer endometrial cancer |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
FGFR2 act mut | Dovitinib | endometrial cancer | sensitive | detail... |
Unknown unknown | Everolimus | endometrial cancer | not applicable | detail... |
Unknown unknown | Pegylated liposomal-doxorubicin + Temsirolimus | endometrial cancer | not applicable | detail... |
Unknown unknown | Dactolisib | endometrial cancer | not applicable | detail... |
Unknown unknown | Sunitinib | endometrial cancer | not applicable | detail... |
Unknown unknown | Adavosertib + Paclitaxel | endometrial cancer | not applicable | detail... |
FGFR2 mutant | Infigratinib | endometrial cancer | sensitive | detail... |
PIK3CA mutant | CH5132799 | endometrial cancer | sensitive | detail... |
PIK3CA H1047Y | CH5132799 | endometrial cancer | sensitive | detail... |
FGFR2 C383R FGFR2 N550K | PD173074 | endometrial cancer | resistant | detail... |
FGFR2 N549K | Ponatinib | endometrial cancer | sensitive | detail... |
FGFR2 N549K | Dovitinib | endometrial cancer | decreased response | detail... |
FGFR2 N549K | Cediranib | endometrial cancer | sensitive | detail... |
FGFR2 N549K | Nintedanib | endometrial cancer | resistant | detail... |
FGFR2 N549K | Brivanib | endometrial cancer | no benefit | detail... |
FGFR2 S252W | Ponatinib | endometrial cancer | sensitive | detail... |
FGFR2 S252W | Cediranib | endometrial cancer | sensitive | detail... |
FGFR2 S252W | Brivanib | endometrial cancer | sensitive | detail... |
FGFR2 S252W | Nintedanib | endometrial cancer | sensitive | detail... |
FGFR2 wild-type | Ponatinib | endometrial cancer | resistant | detail... |
FGFR2 S252W | Dovitinib | endometrial cancer | decreased response | detail... |
FGFR2 - BICC1 FGFR2 - OFD1 | Erdafitinib | endometrial cancer | predicted - sensitive | detail... |
FGFR2 N549K | Debio 1347 | endometrial cancer | sensitive | detail... |
FGFR2 K310R FGFR2 N549K | Debio 1347 | endometrial cancer | sensitive | detail... |
FGFR2 S252W | Debio 1347 | endometrial cancer | sensitive | detail... |
PIK3CA mutant | Pictilisib | endometrial cancer | sensitive | detail... |
PIK3CA mutant | GDC-0980 | endometrial cancer | sensitive | detail... |
AKT1 mutant | GDC-0980 | endometrial cancer | sensitive | detail... |
ALK wild-type | Dalantercept | endometrial cancer | no benefit | detail... |
STK11 inact mut | Sirolimus | endometrial cancer | sensitive | detail... |
Unknown unknown | GSK2126458 | endometrial cancer | not applicable | detail... |
SF3B1 K666N | Spliceostatin A | endometrial cancer | sensitive | detail... |
AKT1 mutant | Temsirolimus | endometrial cancer | predicted - sensitive | detail... |
CTNNB1 mutant | Temsirolimus | endometrial cancer | predicted - sensitive | detail... |
PIK3CA mutant | Temsirolimus | endometrial cancer | no benefit | detail... |
HRAS mutant | Trametinib | endometrial cancer | sensitive | detail... |
Unknown unknown | Everolimus + Letrozole + Metformin | endometrial cancer | not applicable | detail... |
FGFR2 mutant | PRN1371 | endometrial cancer | sensitive | detail... |
FGFR2 K310R FGFR2 N550K | AZD4547 | endometrial cancer | sensitive | detail... |
FGFR2 N550K | AZD4547 | endometrial cancer | predicted - sensitive | detail... |
FGFR2 S252W | AZD4547 | endometrial cancer | decreased response | detail... |
FGFR2 over exp | AZD4547 | endometrial cancer | resistant | detail... |
FGFR2 wild-type | AZD4547 | endometrial cancer | resistant | detail... |
FGFR2 amp | AZD4547 | endometrial cancer | sensitive | detail... |
FGFR2 S252W | E7090 | endometrial cancer | sensitive | detail... |
Unknown unknown | Cediranib | endometrial cancer | not applicable | detail... |
AKT1 E17K | Miransertib | endometrial cancer | sensitive | detail... |
AKT1 E17K | ARQ 751 | endometrial cancer | sensitive | detail... |
Unknown unknown | ETP-46464 + Radiotherapy | endometrial cancer | not applicable | detail... |
Unknown unknown | Cisplatin + ETP-46464 | endometrial cancer | not applicable | detail... |
Unknown unknown | Cisplatin + VE-821 | endometrial cancer | not applicable | detail... |
AKT1 E17K | Capivasertib | endometrial cancer | predicted - sensitive | detail... |
Unknown unknown | ONC201 | endometrial cancer | not applicable | detail... |
Unknown unknown | Capivasertib + Olaparib | endometrial cancer | not applicable | detail... |
ERBB2 mutant | Neratinib | endometrial cancer | no benefit | detail... |
ERBB2 P761del | Neratinib | endometrial cancer | predicted - resistant | detail... |
ERBB2 R678Q | Neratinib | endometrial cancer | no benefit | detail... |
ERBB2 S310F | Neratinib | endometrial cancer | predicted - sensitive | detail... |
ERBB2 S310Y | Neratinib | endometrial cancer | no benefit | detail... |
ERBB2 V697L | Neratinib | endometrial cancer | predicted - resistant | detail... |
ERBB2 V777L | Neratinib | endometrial cancer | predicted - sensitive | detail... |
ERBB2 V842I | Neratinib | endometrial cancer | predicted - resistant | detail... |
FGFR2 S252W | Derazantinib | endometrial cancer | sensitive | detail... |
FGFR2 N549K | Derazantinib | endometrial cancer | sensitive | detail... |
PIK3CA mutant | Alpelisib | endometrial cancer | sensitive | detail... |
Unknown unknown | Lenvatinib + Pembrolizumab | endometrial cancer | not applicable | detail... |
Unknown unknown | Trametinib + Uprosertib | endometrial cancer | no benefit | detail... |
Unknown unknown | Cabozantinib | endometrial cancer | not applicable | detail... |
CTNNB1 mutant | Cabozantinib | endometrial cancer | predicted - sensitive | detail... |
Unknown unknown | LY3023414 | endometrial cancer | not applicable | detail... |
PIK3CA mutant | MK2206 | endometrial cancer | no benefit | detail... |
ARID1A mutant | unspecified PD-L1 antibody | endometrial cancer | predicted - sensitive | detail... |
ARID1A mutant | unspecified PD-1 antibody | endometrial cancer | predicted - sensitive | detail... |
PIK3CA mutant | Perifosine | endometrial cancer | not predictive | detail... |
FGFR2 K310R FGFR2 N550K | Infigratinib + Navitoclax | endometrial cancer | sensitive | detail... |
FGFR2 K310R FGFR2 N550K | Infigratinib | endometrial cancer | sensitive | detail... |
FGFR2 K310R FGFR2 N550K | PD173074 | endometrial cancer | sensitive | detail... |
FGFR2 C383R | AZD4547 | endometrial cancer | sensitive | detail... |
FGFR2 C383R | Infigratinib | endometrial cancer | sensitive | detail... |
FGFR2 C383R | PD173074 | endometrial cancer | sensitive | detail... |
FGFR2 K310R FGFR2 N550K | ABT-737 + AZD4547 | endometrial cancer | sensitive | detail... |
FGFR2 K310R FGFR2 N550K | ABT-737 + Infigratinib | endometrial cancer | sensitive | detail... |
FGFR2 K310R FGFR2 N550K | ABT-737 + PD173074 | endometrial cancer | sensitive | detail... |
FGFR2 C383R | ABT-737 + AZD4547 | endometrial cancer | sensitive | detail... |
FGFR2 C383R | ABT-737 + Infigratinib | endometrial cancer | sensitive | detail... |
FGFR2 C383R | ABT-737 + PD173074 | endometrial cancer | sensitive | detail... |
FGFR2 N550K | ABT-737 + AZD4547 | endometrial cancer | sensitive | detail... |
FGFR2 N550K | ABT-737 + Infigratinib | endometrial cancer | sensitive | detail... |
FGFR2 N550K | ABT-737 + PD173074 | endometrial cancer | sensitive | detail... |
FGFR2 N550K | PD173074 | endometrial cancer | predicted - sensitive | detail... |
FGFR2 N550K | Infigratinib | endometrial cancer | predicted - sensitive | detail... |
Unknown unknown | CC-115 | endometrial cancer | not applicable | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01366144 | Phase I | Paclitaxel Veliparib Carboplatin | Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | Active, not recruiting | USA | 0 |
NCT01379534 | Phase II | Dovitinib | A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer | Completed | USA | 6 |
NCT01697566 | Phase III | Metformin | An Endometrial Cancer Chemoprevention Study of Metformin | Active, not recruiting | USA | 0 |
NCT01797523 | Phase II | Letrozole Everolimus Metformin | RAD/Letrozole/Metformin | Active, not recruiting | USA | 0 |
NCT01874353 | Phase III | Olaparib | Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy | Active, not recruiting | USA | CAN | 15 |
NCT01935934 | Phase II | Cabozantinib | Cabozantinib-S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer | Active, not recruiting | USA | CAN | 0 |
NCT02035787 | Phase I | Metformin | Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients | Recruiting | USA | 0 |
NCT02042495 | Phase II | Metformin | Endometrial Cancer Biomarker Changes Following Exposure to Metformin | Withdrawn | CAN | 0 |
NCT02188550 | Phase II | Everolimus + Letrozole | Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer | Unknown status | USA | 0 |
NCT02269293 | Phase I | Carboplatin + Paclitaxel + Selinexor | Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers | Active, not recruiting | USA | 0 |
NCT02393248 | Phase Ib/II | Cisplatin + Gemcitabine + Pemigatinib Docetaxel + Pemigatinib Pemigatinib + Retifanlimab Pemigatinib + Trastuzumab Epacadostat + Pembrolizumab | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | Recruiting | USA | 1 |
NCT02433626 | Phase I | COTI-2 Cisplatin + COTI-2 | Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101) | Unknown status | USA | 0 |
NCT02501096 | Phase Ib/II | Pembrolizumab Lenvatinib | Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | Active, not recruiting | USA | 2 |
NCT02559492 | Phase I | Epacadostat + Itacitinib Itacitinib + Parsaclisib | INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors | Terminated | USA | 0 |
NCT02584478 | Phase Ib/II | Anlotinib + Carboplatin + Paclitaxel | Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) | Recruiting | USA | 0 |
NCT02606305 | Phase I | Bevacizumab Carboplatin Doxorubicin Mirvetuximab Soravtansine | Study of IMGN853 in Comb. With Bevacizumab, Carboplatin or PLD in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer | Active, not recruiting | USA | CAN | 2 |
NCT02630823 | Phase I | Carboplatin + Paclitaxel + Pembrolizumab | MK-3475 Immunotherapy in Endometrial Carcinoma | Completed | USA | 0 |
NCT02646319 | Phase I | Nab-Rapamycin | Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations | Completed | USA | 0 |
NCT02646748 | Phase I | Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab | Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT02657928 | Phase II | Letrozole + Ribociclib | Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer | Active, not recruiting | USA | 0 |
NCT02661815 | Phase I | Paclitaxel + Ricolinostat Bevacizumab | A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer | Terminated | USA | 0 |
NCT02684227 | Phase II | Carboplatin + Enzalutamide + Paclitaxel | Enzalutamide in Combination With Carboplatin and Paclitaxel in Endometrial Cancer | Recruiting | USA | 0 |
NCT02715284 | Phase I | Dostarlimab | A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors (GARNET) | Recruiting | USA | CAN | 7 |
NCT02725489 | Phase II | Durvalumab + FANG vaccine | Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers | Completed | USA | 0 |
NCT02728258 | Phase II | Copanlisib | Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer | Active, not recruiting | USA | 0 |
NCT02728830 | Phase I | Pembrolizumab | A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers | Active, not recruiting | USA | 0 |
NCT02788708 | Phase I | Lenvatinib + Paclitaxel | Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer | Unknown status | USA | 0 |
NCT02899793 | Phase II | Pembrolizumab | Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer | Active, not recruiting | USA | 0 |
NCT02912572 | Phase II | Avelumab + Talazoparib Avelumab Avelumab + Axitinib | Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer | Recruiting | USA | 0 |
NCT02963831 | Phase Ib/II | Durvalumab + ONCOS-102 | A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies | Recruiting | USA | 0 |
NCT02996825 | Phase I | Gemcitabine + Mirvetuximab Soravtansine | Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT03016338 | Phase II | Niraparib | Study of Niraparib in Recurrent Endometrial Cancer | Recruiting | CAN | 0 |
NCT03065062 | Phase I | Gedatolisib + Palbociclib | Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors | Recruiting | USA | 0 |
NCT03099499 | Phase II | ONC201 | Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer | Recruiting | USA | 0 |
NCT03120624 | Phase I | VSV-hIFNbeta-NIS | VSV-hIFNbeta-NIS in Treating Patients With Stage IV or Recurrent Endometrial Cancer | Recruiting | USA | 0 |
NCT03126110 | Phase Ib/II | INCAGN01876 + Ipilimumab + Nivolumab INCAGN01876 + Nivolumab INCAGN01876 + Ipilimumab | Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | Active, not recruiting | USA | 4 |
NCT03162627 | Phase I | Olaparib + Selumetinib | Selumetinib and Olaparib in Solid Tumors | Recruiting | USA | 0 |
NCT03188965 | Phase I | BAY1895344 | First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas | Recruiting | USA | CAN | 7 |
NCT03300557 | Phase II | Exemestane | Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Grade 1 Endometrial Cancer | Recruiting | USA | 1 |
NCT03310567 | Phase II | Epacadostat + Pembrolizumab | A Study of Pembrolizumab in Combination With Epacadostat in Women With Recurrent/Metastatic Endometrial Carcinoma | Withdrawn | USA | 0 |
NCT03313778 | Phase I | mRNA-4157 + Pembrolizumab mRNA-4157 | Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (KEYNOTE-603) | Recruiting | USA | 0 |
NCT03394027 | Phase II | ONC201 | ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma | Active, not recruiting | USA | 0 |
NCT03410927 | Phase Ib/II | TAS0728 | A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities | Active, not recruiting | USA | 3 |
NCT03454451 | Phase I | CPI-006 CPI-006 + Pembrolizumab CPI-006 + CPI-444 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | Recruiting | USA | 1 |
NCT03474640 | Phase I | Toripalimab | Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies | Recruiting | USA | 0 |
NCT03485729 | Phase II | ONC201 | ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer | Recruiting | USA | 0 |
NCT03508570 | Phase I | Nivolumab Ipilimumab + Nivolumab | Nivolumab With or Without Ipilimumab in Treating Participants With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis | Recruiting | USA | 0 |
NCT03538028 | Phase I | INCAGN02385 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | Completed | USA | 0 |
NCT03552471 | Phase I | Mirvetuximab Soravtansine + Rucaparib | Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Recruiting | USA | 0 |
NCT03555422 | Phase III | Selinexor | Maintenance With Selinexor/Placebo After Combination Chemotherapy in Endometrial Cancer [SIENDO] (SIENDO) | Recruiting | USA | CAN | 6 |
NCT03568539 | Phase Ib/II | Sintilimab | IBI308 in Subjects With Advanced/Metastatic Solid Malignancies | Active, not recruiting | USA | 0 |
NCT03572478 | Phase Ib/II | Nivolumab + Rucaparib Nivolumab Rucaparib | Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer | Terminated | USA | 0 |
NCT03617679 | Phase I | Rucaparib | Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer | Recruiting | USA | 0 |
NCT03628677 | Phase I | AB154 AB154 + GLS-010 | A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies | Recruiting | USA | 1 |
NCT03629756 | Phase I | AB928 + GLS-010 | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | Active, not recruiting | USA | 1 |
NCT03643510 | Phase II | Abemaciclib + Fulvestrant | Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer | Recruiting | USA | 0 |
NCT03667716 | Phase I | COM701 COM701 + Nivolumab | COM701 in Subjects With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT03675893 | Phase II | Abemaciclib + Letrozole | Abemaciclib With Letrozole in Recurrent or Persistent Endometrial Cancer | Recruiting | USA | 0 |
NCT03748186 | Phase I | STRO-002 | Study of STRO-002, an Anti-Folate Receptor Alpha (FolR?) Antibody Drug Conjugate in Ovarian & Endometrial Cancers | Recruiting | USA | 0 |
NCT03835819 | Phase II | Mirvetuximab Soravtansine + Pembrolizumab | A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC) | Recruiting | USA | 0 |
NCT03905148 | Phase Ib/II | BGB-283 + PD-0325901 | Study of the Safety and Pharmacokinetics of BGB-283 (Lifirfenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors | Recruiting | USA | 1 |
NCT03936959 | Phase I | LY3434172 | A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer | Active, not recruiting | USA | 4 |
NCT03964727 | Phase II | Sacituzumab govitecan-hziy | A Study of Sacituzumab Govitecan in Metastatic Solid Tumors (Tropics-03) | Suspended | USA | 0 |
NCT03968406 | Phase I | Talazoparib | Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers | Recruiting | USA | 0 |
NCT03981796 | Phase III | Carboplatin + Paclitaxel Carboplatin + Dostarlimab + Paclitaxel | A Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY) | Recruiting | USA | CAN | 17 |
NCT04096638 | Phase I | Nivolumab + SB 11285 SB 11285 | Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04122625 | Phase Ib/II | Debio 1143 + Nivolumab | Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143 (SMARTPLUS-106) | Recruiting | USA | 2 |
NCT04145622 | Phase Ib/II | DS-7300a | Study of DS-7300a in Participants With Advanced Solid Malignant Tumors | Recruiting | USA | 1 |
NCT04152018 | Phase I | PF-06801591 + PF-06940434 PF-06940434 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | Recruiting | USA | 0 |
NCT04188548 | Phase I | Abemaciclib + LY3484356 LY3484356 Abemaciclib + LY3484356 + Trastuzumab Abemaciclib + Anastrozole + LY3484356 Abemaciclib + Exemestane + LY3484356 Alpelisib + LY3484356 Everolimus + LY3484356 Abemaciclib + Letrozole + LY3484356 | A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer (EMBER) | Recruiting | USA | 7 |
NCT04197219 | Phase II | Axitinib + Pembrolizumab | Pembrolizumab With Axitinib in Recurrent Endometrial Cancer | Withdrawn | 0 | |
NCT04214067 | Phase III | Pembrolizumab | Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer | Recruiting | USA | 1 |
NCT04300556 | Phase Ib/II | MORAb-202 | A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FR alpha)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types | Recruiting | USA | 0 |
NCT04319757 | Phase I | ACE1702 + Cyclophosphamide + Fludarabine | ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors | Recruiting | USA | 0 |
NCT04395079 | Phase II | Tremelimumab Durvalumab | Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies | Recruiting | USA | 0 |
NCT04423029 | Phase Ib/II | DF6002 + Pembrolizumab DF6002 | Dose Escalation of DF6002 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications | Recruiting | USA | 0 |
NCT04463771 | Phase II | Pemigatinib + Retifanlimab Epacadostat + Retifanlimab Retifanlimab | Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy. (POD1UM-204) | Recruiting | USA | 0 |
NCT04482309 | Phase II | Trastuzumab deruxtecan | A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors (DPT02) | Recruiting | USA | CAN | 11 |
NCT04498520 | Phase I | Abexinostat + Fulvestrant + Palbociclib | Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer | Not yet recruiting | USA | 0 |
NCT04521413 | Phase Ib/II | CFI-402411 + Pembrolizumab CFI-402411 | Safety and Efficacy Study Of CFI-402411 in Subjects With Advanced Solid Malignancies | Recruiting | USA | CAN | 1 |
NCT04570839 | Phase Ib/II | BMS-986207 + COM701 + Nivolumab Nivolumab | COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. | Recruiting | USA | 0 |
NCT04682431 | Phase I | Pembrolizumab + PY159 PY159 | A Phase 1a/1b First-In-Human (FIH) Study of PY159 in Subjects With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04750941 | Phase II | Copanlisib | Study of Copanlisib and Ketogenic Diet | Recruiting | USA | 0 |